

Dignitana AB (publ)

Lund, Sweden, OCTOBER 28, 2015

Dignitana To Exhibit DigniCap® at San Antonio Breast Cancer Symposium

First Scalp Cooling Device to Complete a Formal Trial for U.S. FDA Approval Will Be On Display At Gathering of World's Leading Breast Cancer Researchers and Physicians This December

Dignitana, a world leader in medical scalp cooling technology, has announced that the scalp cooling system DigniCap®, for the prevention of chemotherapy related hair loss, will be exhibited at the 2015 San Antonio Breast Cancer Symposium (SABCS). One of the world's most important gatherings of academic and private breast cancer physicians and researchers, SABCS provides state-of-the-art information and updates based on the latest breast cancer medical research and scientific advances.

Scalp cooling devices for the reduction of chemotherapy related alopecia have been in wide use throughout Europe, but no device has yet been cleared for use in the United States. DigniCap® is the only scalp-cooling device to have completed a formal trial for U.S. FDA approval; the device is currently pending FDA Clearance. DigniCap® has been clinically tested with breast cancer patients who received positive results at some of the most renowned medical centers in the U.S.

Scalp cooling is now experiencing increased interest from both doctors and patients. Dignitana's goal is to continue to raise awareness and knowledge about scalp cooling and DigniCap®. Dignitana will, for the first time, display DigniCap® at the symposium.

Jan Richardsson, CEO Dignitana AB (publ):

"The time is right to introduce DigniCap® at SABCS to physicians who are eager to provide their patients with an alternative to one of the most distressful side effects of chemotherapy. We are currently in the absolute final stages of the regulatory process for FDA approval in the United States for DigniCap®. I am convinced that DigniCap® will be approved. It has been a long process, but pending the approval we are working hard to establish contacts with potential customers and negotiate contracts with hospitals. We are very eager to bring this important technology to market."

Media Contact:

Caren Browning King + Company

Phone: 00 1 212 561-7464

Email: Caren.Browning@kingcompr.com

Jan Richardsson

CEO, Dignitana AB (publ) **Phone**: +46 46 16 30 92

Email: jan.richardsson@dignitana.se

About Dignitana AB (publ)

Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana is continuously researching and developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bankaktiebolag as Certified Advisor. For more information visit www.dignitana.com

About the scalp cooling system DigniCap®

Dignitana's core product - DigniCap® - is a patented scalp-cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® is developed to provide continuous cooling with high efficacy, safety and acceptable patient comfort.